Innate Pharma
IPHA
12 hedge funds and large institutions have $1.89M invested in Innate Pharma in 2022 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0.01% less ownership
Funds ownership: 1.2% → 1.18% (-0.01%)
8% less funds holding
Funds holding: 13 → 12 (-1)
27% less capital invested
Capital invested by funds: $2.58M → $1.89M (-$687K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$43.4K |
| 2 |
Morgan Stanley
New York
|
+$27.7K |
| 3 |
Optiver Holding
Amsterdam,
Netherlands
|
+$9.08K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.18K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$478 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$39.5K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$28.2K |
| 3 |
Two Sigma Investments
New York
|
-$17.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7K |
| 5 |
Millennium Management
New York
|
-$6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
BlackRock
New York
| $965K | -$39.5K | -14,630 | -3% |
|
|
2
Optiver Holding
Amsterdam,
Netherlands
| $371K | +$9.08K | +3,366 | +2% |
|
|
3
Bank of America
Charlotte,
North Carolina
| $330K | -$28.2K | -10,451 | -6% |
|
|
4
Morgan Stanley
New York
| $114K | +$27.7K | +10,254 | +22% |
|
|
5
Two Sigma Investments
New York
| $38K | -$17.5K | -6,500 | -26% |
|
|
6
Balyasny Asset Management
Chicago,
Illinois
| $32K | +$43.4K | +16,094 | New |
|
|
7
Millennium Management
New York
| $29K | -$6K | -2,222 | -13% |
|
|
8
UBS Group
Zurich,
Switzerland
| $9K | +$4.18K | +1,549 | +52% |
|
|
SPIA
9
Steward Partners Investment Advisory
New York
| $1K | – | – | – |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| – | -$7K | -2,600 | Closed |
|
11
Barclays
London,
United Kingdom
| – | -$5.55K | -2,056 | -94% |
|
|
CS
12
Credit Suisse
Zurich,
Switzerland
| – | -$5K | -1,981 | Closed |
|
13
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| – | -$2K | -905 | Closed |
|
14
Citigroup
New York
| – | -$3 | -1 | -2% |
|
|
15
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$478 | +177 | New |
|
IPHA Hedge Fund Activity: Q3 2022 in Review
12 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Innate Pharma (IPHA) for Q3 2022, worth a combined $1.89M — down 27% from $2.58M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of IPHA and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 3 added.
The largest buyer was Balyasny Asset Management, opening a new position worth an estimated $43.4K. The largest seller was BlackRock, cutting an estimated $39.5K.
- 12 institutional investors held Innate Pharma (IPHA) as of Q3 2022, down from 13 in Q2 2022.
- Funds reported $1.89M of Innate Pharma stock for Q3 2022, down 27% quarter-over-quarter.
- 2 funds opened new Innate Pharma positions in Q3 2022 and 3 closed out, a net change of -1 holder.
- The largest Innate Pharma buyer in Q3 2022 was Balyasny Asset Management, an estimated $43.4K added.
- The largest Innate Pharma seller in Q3 2022 was BlackRock, an estimated $39.5K sold.
Based on aggregated 13F filings for Q3 2022.